Ancient herbal remedy put to the test against Diabetes' nerve damage
NCT ID NCT07771894
First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time
Summary
This trial tests whether a traditional Chinese herbal formula, Zuogui Jiangtang Shuluo, can improve nerve function and reduce symptoms in people with diabetic peripheral neuropathy, a common complication of type 2 diabetes that causes pain, numbness, and tingling. Participants will receive either the herbal formula or a standard vitamin B12-like medication (mecobalamin) for four weeks. The study will measure changes in nerve conduction and symptom scores, and also analyze blood samples to explore how the formula might work at a molecular level.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Zuogui Jiangtang Shuluo Formula (a traditional Chinese herbal decoction)
- What this could lead to
- If effective, this herbal formula could offer a safer, additional option to help manage diabetic nerve damage and reduce symptoms like pain and numbness.
- What could go wrong
- This is a small, early-stage study. The formula's benefits are uncertain, and herbal remedies can have side effects or interact with other medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 74 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
35 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
DSPN inclusion criteria: 1. Meet the diagnostic criteria for type 2 diabetes mellitus with distal symmetric polyneuropathy (DSPN) according to Western medicine standards. 2. Meet the TCM syndrome differentiation criteria for consumptive thirst complicated with arthromyodynia of the pattern of Qi-Yin deficiency with blood stasis. 3. Glycated hemoglobin (HbA1c) between 6.5% and 9.0% (inclusive). 4. Aged 35 to 75 years (inclusive) at the time of screening, regardless of gender. 5. Have not participated in any other clinical trial within 2 weeks prior to the start of treatment, and have not taken lipid-lowering agents, antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, immunosuppressants, or other traditional Chinese medicines that may affect metabolomic and lipidomic profiles. 6. Willing to voluntarily participate in the trial and adhere to the 4-week traditional Chinese medicine treatment regimen. 7. Right-handed. 8. Provide written informed consent and are able to understand and comply with the study protocol requirements, including dietary and exercise recommendations and blood glucose monitoring. DSPN exclusion criteria 1. Patients with type 1 diabetes mellitus or other specific types of diabetes mellitus. 2. Women who are pregnant, breastfeeding, planning pregnancy, or taking oral contraceptives long-term. 3. Neuropathies caused by other conditions, including but not limited to multiple sclerosis, Parkinson's disease, Guillain-Barré syndrome, epilepsy, spinal cord injury, cervical or lumbar spine lesions (nerve root compression, spinal stenosis, cervical or lumbar degenerative diseases), neuromuscular diseases, severe arterial or venous vascular diseases (venous thrombosis, lymphangitis, etc.), sequelae of cerebrovascular disease, or post-surgical status of lower extremity vasculature. 4. History of stroke, transient ischemic attack, unstable angina, or myocardial infarction within 3 months prior to study enrollment. 5. History of acute diabetic complications (diabetic ketoacidosis, lactic acidosis, or hyperosmolar hyperglycemic state) within 3 months prior to study enrollment. 6. Concomitant severe complications of diabetes, such as end-stage diabetic kidney disease, or proliferative diabetic retinopathy. 7. Concomitant severe diseases of the heart, liver, kidney, cerebrovascular system, or malignant tumors, defined as serum creatinine \>200 μmol/L, blood urea nitrogen \>1.5 times the upper limit of normal, or alanine aminotransferase or aspartate aminotransferase \>3 times the upper limit of normal. 8. Any infection that, in the investigator's opinion, makes the patient unsuitable for participation prior to study enrollment, including but not limited to urinary tract infection, respiratory infection, or diabetic foot with infection requiring further treatment. 9. Patients with psychiatric disorders, cognitive impairment, or inability to cooperate with the study procedures; or individuals with a history of alcohol abuse or drug addiction. Healthy volunteer inclusion criteria: 1. Aged 18 to 55 years (inclusive) at the time of screening, regardless of gender. 2. Body mass index (BMI) within the range of 19.0 to 26.0 kg/m² (inclusive). No severe diseases of the heart, liver, kidney, cerebrovascular system, or malignant tumors; routine laboratory tests, electrocardiogram, and chest X-ray are essentially within normal limits. 3. Have not participated in any other clinical trial within 2 weeks prior to the start of treatment, and have not taken lipid-lowering agents, antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants, immunosuppressants, or other traditional Chinese medicines that may affect metabolomic and lipidomic profiles. 4. Voluntarily sign the informed consent form and are willing and able to cooperate with the investigators to complete the clinical study. Healthy volunteer exclusion criteria: 1. Women who are pregnant, breastfeeding, planning pregnancy, or taking oral contraceptives long-term. 2. Patients with psychiatric disorders, cognitive impairment, or inability to cooperate with the study procedures. 3. Individuals with a history of alcohol abuse or drug addiction.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic peripheral neuropathy (DPN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Changsha, Hunan, 410000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vitamin b derivative beat standard b vitamins for diabetic nerve pain?
- New ultrasound and blood test could spot diabetic nerve damage sooner
- Can simple foot exercises prevent falls in diabetics?
- Could a daily 5-Minute mask soothe nerve pain?
- Can acupuncture needles zap away diabetic nerve pain?
- Scientists hunt for blood clues to spot diabetic nerve pain early